Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 379-387, June 2008

A Comparison of Patient and Physician-Rated New York Heart Association Class in a Community-Based Heart Failure Clinic

Department of Cardiology, Castle Hill Hospital, Kingston-upon-Hull, United Kingdom

Received 12 September 2007; received in revised form 21 January 2008; accepted 23 January 2008. published online 07 April 2008.

Abstract 

Objective

The New York Heart Association (NYHA) classification is recommended for grading symptoms of chronic heart failure and is a powerful prognostic marker. Patient-rated NYHA (Pa-NYHA) and physician-rated NYHA (Dr-NYHA) class have never been compared directly, and it is unknown whether they carry similar prognostic significance.

Methods and Results

NYHA class was rated independently by a physician and patient in 1752 patients referred with suspected heart failure. Pa-NYHA and Dr-NYHA varied by 1 class in 37.1% cases and by 2 classes in 12.8% cases. Mean Dr-NYHA and Pa-NYHA were higher in women than men (1.98 vs 1.89, P = .016; 2.17 vs 2.02, P = .002) despite less cardiac disease. Dr-NYHA correlated more with 6-minute walk test distance and severity of left ventricular systolic dysfunction than Pa-NYHA (Spearman's ρ: −0.53 vs −0.44 and 0.32 vs 0.16). Dr-NYHA better predicted mortality when compared with Pa-NYHA (log-rank: χ2 = 105 vs 46, both P < .001).

Conclusion

Patients rate NYHA differently from physicians, and women rate NYHA differently from men. Dr-NYHA relates more strongly to survival and severity of left ventricular systolic dysfunction, suggesting that for physicians the NYHA classification may have become a “heart failure severity score” and not as was intended, purely a measure of a patient's symptoms and functional status.

Key Words: Heart failure, Prognosis, Symptom score

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Cleland has received grants and speakers' honoraria from Roche Diagnostics related to the clinical use of natriuretic peptides. Dr Goode has received travel and accommodation grants for conference presentation from Roche Diagnostics. Drs Clark and Nabb have no conflicts of interest.

PII: S1071-9164(08)00042-0

doi:10.1016/j.cardfail.2008.01.014

Journal of Cardiac Failure
Volume 14, Issue 5 , Pages 379-387, June 2008